Prescribing Omnipod® 5 may help to improve glycaemic control and ease the burden of type 1 diabetes (T1D) care*1-3
Making the change to Omnipod® 5 need not be a challenge for either you or your patients, and the benefits of doing so are clear. See how it could help to improve your T1D control for your patients from 2 years of age, with a system that adjusts to their needs and supports them every step of the way.
Flexibility to suit your patients’ needs: the OmnipodPromiseTM
We all know how important it is to ensure that patients are happy and satisfied with their treatment. Making a switch is not always an easy decision.
At Insulet, we are aware that four-year warranty periods on insulin pumps are typically viewed as ‘lock-in’ periods and a potential barrier to patient choice. That’s why we strive to take steps to facilitate flexibility and reduce lock-in periods on the diabetes pump technology landscape. The actual steps we take may vary by location.
If you have any questions, request a call back from a representative.
Everything you need to know about prescribing Omnipod® 5
Supporting you and your patients every step of the way
The Omnipod Product Specialist team are on hand to introduce people with T1D to Pod therapy, and to answer any technical questions that they or you may have. We also offer a variety of resources for education and support:
- Your patients can experience the comfort and convenience of the Pod first-hand with the Pod Experience Kit, which includes a needle-free Pod that does not deliver insulin (The controller is not included)
- 1-hour live Virtual Show and Tell sessions
- How-to videos, resources and more
What the Omnipod® 5 System provides for your patients and practice
Omnipod® 5 puts simplified T1D
Omnipod® 5 puts simplified T1D management into your patients’ hands. At its heart is SmartAdjust™ technology, proactively managing insulin delivery every 5 minutes using a customised glucose target to help minimise time in hyperglycaemia and hypoglycaemia.*†‡§1,2
Track patient progress
Get up-to-date patient data to evaluate their progress with the Glooko® platform, which enables wireless data uploads to support remote and in-person care. Support treatment decisions with actionable insights that combine sensor and insulin data, with rapid identification of trends for personalised care.
* Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
† When used in automatic mode with Dexcom G6 sensor, the Omnipod® 5 System makes adjustments to insulin delivery every 5 minutes based on the user’s current sensor value, glucose values predicted 60 minutes in the future, glucose trend and past insulin delivery to bring glucose to a user-defined target. Requires a Dexcom G6 sensor. User will still require boluses before meals that contain carbohydrates and to correct high glucose levels.
‡ If glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, a blood glucose meter should be used to make diabetes treatment decisions.
§ Dexcom G6 sensor sold separately. The Omnipod® 5 System must be used with the Dexcom G6 app and is not compatible with the Dexcom G6 receiver.
Choosing an insulin for Omnipod® 5
Omnipod® 5 gives you the choice of a variety of rapid-acting U-100 insulins, so that you can prescribe the one that’s right for your patient.
The following insulins have been tested and found safe for use with Omnipod 5:*
Which patients may benefit from making the switch to Omnipod® 5?
Patients who find diabetes management complex
Simplify Life® with Omnipod® 5 automated insulin delivery, incorporating Dexcom G6 and SmartAdjust™ technology to make effective T1D care an achievable goal.
Patients struggling to maintain glycaemic control
National audit data demonstrates that 90% of adults and 88% of children are not meeting recommended HbA1c targets of 6.5% (48 mmol/mol).4,5 Omnipod® 5 delivered significant improvements vs prior therapy (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII]) across key glycaemic parameters for users aged 2 years and older in two pivotal prospective clinical trials.*1,2
Patients who feel burdened by diabetes management
Help your patients realise the freedom and flexibility of on-body, personalised, adaptive T1D control. Using Omnipod® 5 has been shown to decrease diabetes distress, potentially helping to ease the substantial burden of T1D management.3
Prescribing Omnipod® 5 for children
Adjusting over time to your young patients’ needs, with SmartAdjust™ technology to help protect them against highs and lows*†
Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so children can continue their AID when swimming or bathing
- Improved glycaemic outcomes that go hand-in-hand with improved quality of life and mental well-being reported by parents of children with T1D†1-3
Prescribing Omnipod® 5 for adults
Adjusting over time to your patients’ needs, with SmartAdjust™ technology to help to protect them against highs and lows*†
Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so that adults can live their lives without interrupting their AID
- Improved glycaemic outcomes that go hand-in-hand with improved patient-reported outcomes such as diabetes distress and stress when eating†1,2
† Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
‡ The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 m (8 feet) of water for up to 24 hours without failure when properly installed.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. By signing up for our mailing list, you will be in the know when it comes to training and events, Omnipod® published data and first-hand experiences from Podders®.
References: 1. Brown SA et al. Diabetes Care 2021;44(7):1630-1640. 2. Sherr J et al. Diabetes Care 2022;45:1907-1910. 3. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. 4. National Diabetes Audit 2020/2021. England and Wales. https://www.hqip.org.uk/wp-content/uploads/2022/06/REF241_NDA-TYPE1-REP-v20220615_FINAL.pdf [Accessed June 2023]. 5. National Paediatric Diabetes Audit 2020/2021. England and Wales. Available at: https://www.rcpch.ac.uk/sites/default/files/2022-04/NPDA%20report%202020-21%20Appendix%201%20Full%20audit%20analysis_0.pdf [Accessed June 2023].